<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530712</url>
  </required_header>
  <id_info>
    <org_study_id>P-2424</org_study_id>
    <nct_id>NCT00530712</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis</brief_title>
  <acronym>DURABILITY II</acronym>
  <official_title>The US StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol STent SYstem II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, non-randomized, single arm study to compare PTA and primary stenting
      using a single PROTÉGÉ® EverFlex™ stent to performance goals of PTA alone in the treatment of
      atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>1 Year</time_frame>
    <description>Primary stent patency, as determined by the core laboratory, was defined as PSV ratio &lt; 2.0 at the stented target lesion as measured by duplex ultrasound at the 1-year follow-up visit (335-395 days post procedure) and no clinically-driven TLR within the stented segment within 1 year of the procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>30 Days</time_frame>
    <description>Major Adverse Events (MAE) was defined as clinically-driven Target Lesion Revascularization (TLR), amputation of treated limb, or all-cause mortality, as adjudicated by the Clinical Events Commettee (CEC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single-Stent Primary Patency</measure>
    <time_frame>1 Year</time_frame>
    <description>Primary stent patency in subjects with single-stent, as determined by the core laboratory, was defined as PSV ratio &lt; 2.0 at the stented target lesion as measured by duplex ultrasound at the 1-year follow-up visit (335-395 days post procedure) and no clinically-driven TLR within the stented segment within 1 year of the procedure. Single stents were implanted in 272 subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-Stent Major Adverse Events</measure>
    <time_frame>30 Days</time_frame>
    <description>MAE rate in subjects who received a single stent was defined as clinically-driven TLR, amputation of treated limb, or all-cause mortality that occurred within 30-days post-procedure, as adjudicated by the CEC. Single stents were implanted in 272 subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>1 Year</time_frame>
    <description>MAE rate at 1 year was defined as clinically-driven TLR, amputation of treated limb, or all-cause mortality that occurs within 1 year post-procedure, as adjudicated by the CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Fracture Rate</measure>
    <time_frame>1, 2 and 3 Years</time_frame>
    <description>Stent integrity determined by x-ray at 1, 2 and 3 years post stent implantation. only 1 year data presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in Rutherford Clinical Category</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as an increase of one or more categories in RCC compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Rutherford Clinical Category</measure>
    <time_frame>1 Year</time_frame>
    <description>Improvement in Rutherford Clinical Category (RCC) was defined as an improvement in clinical status indicated by a decrease of one or more categories in RCC compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in Ankle-Brachial Index</measure>
    <time_frame>1 Year</time_frame>
    <description>Defined as an increase in ancle-brachial index (ABI) at 1 year compared to baseline in subjects with compressible arteries and baseline ABI &lt; 0.9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Primary Patency</measure>
    <time_frame>1 Year</time_frame>
    <description>Assisted primary patency at 1 year was defined as PSV ratio &lt; 2.0 as measured by binary duplex ultrasound maintained by repeated percutaneous intervention completed prior to complete vessel closure. Kaplan-Meier assisted primary patency was evaluated in all enrolled subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>1 Year</time_frame>
    <description>Secondary patency was defined as PSV ratio &lt; 2.0 maintained by repeat percutaneous intervention after occlusion of the target lesion. Secondary patency was evaluated by the Kaplan-Meier method in all enrolled subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Claudication Distance Improvement</measure>
    <time_frame>1 Year</time_frame>
    <description>Absolute claudication distance improvement at 1 year was defined as the increase in walking distance determined by a graded treadmill exercise test. Only assessed in subjects enrolled under study procol versions in which the endpoint was predefined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Improvement</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duplex Ultrasound ≤ 2.4 Primary Patency</measure>
    <time_frame>1 Year</time_frame>
    <description>Defined as a binary duplex ultrasound ratio ≤ 2.4 at the stented target lesion with no clinically-driven reintervention without the stented segment. Duplex Ultrasound ≤ 2.4 primary patency was evaluated by the Kaplan-Meier method in all enrolled subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">287</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Claudication</condition>
  <arm_group>
    <arm_group_label>PTA and Stenting with EverFlex device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Qualified subjects undergo treatment of atherosclerotic lesions in the native SFA/SFA/PPA with PTA and stenting using the PROTÉGÉ® EverFlex™ Self-Expanding Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROTÉGÉ® EverFlex™ Self-Expanding Stent System</intervention_name>
    <description>Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.</description>
    <arm_group_label>PTA and Stenting with EverFlex device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stenotic, restenotic (from PTA or adjunct therapy, not including stents or stent
             grafts) or occluded lesion(s) located in the native superficial femoral artery or
             superficial femoral and proximal popliteal arteries.

          -  Symptomatic femoral-popliteal atherosclerosis.

          -  Willing to comply with all follow-up evaluations at the specified times.

          -  Provides written informed consent prior to enrollment in the study.

        Exclusion Criteria:

          -  Previously implanted stent(s) or stent graft(s) in the target vessel.

          -  Planned use of devices other than angioplasty balloons during procedure.

          -  Received endovascular treatment of the target lesion (except stents/stent grafts)
             within six months of the index procedure.

          -  Life expectancy of less than 12 months.

          -  Symptomatic femoral disease in the opposite limb.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Matsumura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krishna Rocha-Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prairie Heart Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW, Bosiers M, Schultz GA, Scheinert D, Rocha-Singh KJ. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II). J Vasc Surg. 2013 Jul;58(1):73-83.e1. doi: 10.1016/j.jvs.2012.12.066. Epub 2013 May 2.</citation>
    <PMID>23642924</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2007</study_first_submitted>
  <study_first_submitted_qc>September 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2007</study_first_posted>
  <results_first_submitted>July 28, 2014</results_first_submitted>
  <results_first_submitted_qc>July 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SFA</keyword>
  <keyword>Popliteal</keyword>
  <keyword>Stent</keyword>
  <keyword>EverFlex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
          <description>Subjects recieved the EverFlex™ Peripheral Self-Expanding Stent System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrollment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287">Total Enrolled Subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287">Subjects Available at Discharge</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>30 Day Follow-up Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287">Subjects Expected for 30-Day Visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="280">Subjects that Completed 30-Day Follow-up Visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>6 Month Follow-up Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287">Subjects Expected for 6-Month Visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="275">Subjects that Completed 6-Month Follow-up Visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12 Month Follow-up Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287">Subjects Expected for 12 Month Visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263">Subjects that Completed 12-Month Follow-up Visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
          <description>Subjects recieved the EverFlex™ Peripheral Self-Expanding Stent System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Patency</title>
        <description>Primary stent patency, as determined by the core laboratory, was defined as PSV ratio &lt; 2.0 at the stented target lesion as measured by duplex ultrasound at the 1-year follow-up visit (335-395 days post procedure) and no clinically-driven TLR within the stented segment within 1 year of the procedure.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Primary stent patency, as determined by the core laboratory, was defined as PSV ratio &lt; 2.0 at the stented target lesion as measured by duplex ultrasound at the 1-year follow-up visit (335-395 days post procedure) and no clinically-driven TLR within the stented segment within 1 year of the procedure.</description>
          <units>Percentage of participants with data</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Events</title>
        <description>Major Adverse Events (MAE) was defined as clinically-driven Target Lesion Revascularization (TLR), amputation of treated limb, or all-cause mortality, as adjudicated by the Clinical Events Commettee (CEC)</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex™ Peripheral Self-Expanding Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Events</title>
          <description>Major Adverse Events (MAE) was defined as clinically-driven Target Lesion Revascularization (TLR), amputation of treated limb, or all-cause mortality, as adjudicated by the Clinical Events Commettee (CEC)</description>
          <units>Percentage of participants with data</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single-Stent Primary Patency</title>
        <description>Primary stent patency in subjects with single-stent, as determined by the core laboratory, was defined as PSV ratio &lt; 2.0 at the stented target lesion as measured by duplex ultrasound at the 1-year follow-up visit (335-395 days post procedure) and no clinically-driven TLR within the stented segment within 1 year of the procedure. Single stents were implanted in 272 subject.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Single-Stent Primary Patency</title>
          <description>Primary stent patency in subjects with single-stent, as determined by the core laboratory, was defined as PSV ratio &lt; 2.0 at the stented target lesion as measured by duplex ultrasound at the 1-year follow-up visit (335-395 days post procedure) and no clinically-driven TLR within the stented segment within 1 year of the procedure. Single stents were implanted in 272 subject.</description>
          <units>Percentage of participants with data</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single-Stent Major Adverse Events</title>
        <description>MAE rate in subjects who received a single stent was defined as clinically-driven TLR, amputation of treated limb, or all-cause mortality that occurred within 30-days post-procedure, as adjudicated by the CEC. Single stents were implanted in 272 subjects.</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Single-Stent Major Adverse Events</title>
          <description>MAE rate in subjects who received a single stent was defined as clinically-driven TLR, amputation of treated limb, or all-cause mortality that occurred within 30-days post-procedure, as adjudicated by the CEC. Single stents were implanted in 272 subjects.</description>
          <units>Percentage of participants with data</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Events</title>
        <description>MAE rate at 1 year was defined as clinically-driven TLR, amputation of treated limb, or all-cause mortality that occurs within 1 year post-procedure, as adjudicated by the CEC.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Events</title>
          <description>MAE rate at 1 year was defined as clinically-driven TLR, amputation of treated limb, or all-cause mortality that occurs within 1 year post-procedure, as adjudicated by the CEC.</description>
          <units>Percentage of particants with data</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically-driven TLR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Fracture Rate</title>
        <description>Stent integrity determined by x-ray at 1, 2 and 3 years post stent implantation. only 1 year data presented here.</description>
        <time_frame>1, 2 and 3 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Fracture Rate</title>
          <description>Stent integrity determined by x-ray at 1, 2 and 3 years post stent implantation. only 1 year data presented here.</description>
          <units>percentage of stents implanted</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Stent Implanted</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decline in Rutherford Clinical Category</title>
        <description>Defined as an increase of one or more categories in RCC compared to baseline.</description>
        <time_frame>30 Days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Rutherford Clinical Category</title>
        <description>Improvement in Rutherford Clinical Category (RCC) was defined as an improvement in clinical status indicated by a decrease of one or more categories in RCC compared to baseline.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Rutherford Clinical Category</title>
          <description>Improvement in Rutherford Clinical Category (RCC) was defined as an improvement in clinical status indicated by a decrease of one or more categories in RCC compared to baseline.</description>
          <units>Percentage of participants with data</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Ankle-Brachial Index</title>
        <description>Defined as an increase in ancle-brachial index (ABI) at 1 year compared to baseline in subjects with compressible arteries and baseline ABI &lt; 0.9.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Ankle-Brachial Index</title>
          <description>Defined as an increase in ancle-brachial index (ABI) at 1 year compared to baseline in subjects with compressible arteries and baseline ABI &lt; 0.9.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Primary Patency</title>
        <description>Assisted primary patency at 1 year was defined as PSV ratio &lt; 2.0 as measured by binary duplex ultrasound maintained by repeated percutaneous intervention completed prior to complete vessel closure. Kaplan-Meier assisted primary patency was evaluated in all enrolled subjects.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Primary Patency</title>
          <description>Assisted primary patency at 1 year was defined as PSV ratio &lt; 2.0 as measured by binary duplex ultrasound maintained by repeated percutaneous intervention completed prior to complete vessel closure. Kaplan-Meier assisted primary patency was evaluated in all enrolled subjects.</description>
          <units>Event free percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9" lower_limit="82.1" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>Secondary patency was defined as PSV ratio &lt; 2.0 maintained by repeat percutaneous intervention after occlusion of the target lesion. Secondary patency was evaluated by the Kaplan-Meier method in all enrolled subjects.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <description>Secondary patency was defined as PSV ratio &lt; 2.0 maintained by repeat percutaneous intervention after occlusion of the target lesion. Secondary patency was evaluated by the Kaplan-Meier method in all enrolled subjects.</description>
          <units>Event free percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="82.6" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Claudication Distance Improvement</title>
        <description>Absolute claudication distance improvement at 1 year was defined as the increase in walking distance determined by a graded treadmill exercise test. Only assessed in subjects enrolled under study procol versions in which the endpoint was predefined.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Claudication Distance Improvement</title>
          <description>Absolute claudication distance improvement at 1 year was defined as the increase in walking distance determined by a graded treadmill exercise test. Only assessed in subjects enrolled under study procol versions in which the endpoint was predefined.</description>
          <units>Miles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Improvement</title>
        <time_frame>1 Year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duplex Ultrasound ≤ 2.4 Primary Patency</title>
        <description>Defined as a binary duplex ultrasound ratio ≤ 2.4 at the stented target lesion with no clinically-driven reintervention without the stented segment. Duplex Ultrasound ≤ 2.4 primary patency was evaluated by the Kaplan-Meier method in all enrolled subjects.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
            <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
          </group>
        </group_list>
        <measure>
          <title>Duplex Ultrasound ≤ 2.4 Primary Patency</title>
          <description>Defined as a binary duplex ultrasound ratio ≤ 2.4 at the stented target lesion with no clinically-driven reintervention without the stented segment. Duplex Ultrasound ≤ 2.4 primary patency was evaluated by the Kaplan-Meier method in all enrolled subjects.</description>
          <units>Event free percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" lower_limit="72.4" upper_limit="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EverFlex™ Peripheral Self-Expanding Stent System</title>
          <description>Subjects recieved the EverFlex Peripheral Self-Expanding Stent</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Access site complication - Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Access site complication - Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute Stent Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Allergic reaction to contrast dye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Allergic reaction to procedure meds</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Amputation of treated limb above metatarsal line</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Amputation of treated limb below metatarsal line</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Artery perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Other Respiratory Issues</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Other Vascular Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Percutaneous revascularization of target vessel</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Stent misplacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Stent/Vessel thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Other Cardiac Disorders</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Other Bleeding/lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other Infections</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other Musculoskeletal disorders</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Other Vascular Disorders</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie Cihlar</name_or_title>
      <organization>Medtronic</organization>
      <phone>763-398-7932</phone>
      <email>stephanie.a.cihlar@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

